Principal Director The George Institute for Global Health
- Board Member, The George Institute for Global Health
- Professor of Cardiovascular medicine at Sydney University
- Professor of Medicine at Oxford University
Stephen is one of the founders of The George Institute for Global Health, an architect of its global expansion and currently holds the position of Principal Director of The George Institute for Global Health (worldwide).
He also holds professorial appointments in medicine at both the University of Sydney (Australia) and the University of Oxford (UK), where he is a James Martin Professorial Fellow. Stephen is an international authority on the causes, prevention and treatment of cardiovascular diseases and has a special interest is the management of chronic and complex conditions in resource-poor settings, particularly in the Asia-Pacific region.
In addition to his Institute and university appointments, Stephen holds several external appointments, including those as Chair of the International Scientific Board of the UK BioBank. He is also Executive Chair of George Clinical Pty Ltd, a wholly owned subsidiary of The George Institute. He sits on the Boards of several other not-for-profit organisations, including the Oxford Health Alliance.
Stephen has published more than 300 scientific papers and delivered more than 200 invited lectures. For his work in the field of cardiovascular disease, he has received numerous awards, fellowships and honours from various governments, universities and learned societies.
Elevated blood pressure and risk of mitral regurgitation: A longitudinal cohort study of 5.5 million United Kingdom adults.
Rahimi K. et al, (2017), PLoS medicine, 14, e1002404 - e1002404
The Effects of a Community-Based Sodium Reduction Program in Rural China – A Cluster-Randomized Trial
Li N. et al, (2016), PLOS ONE, 11, e0166620 - e0166620
Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R. et al, (2016), Lancet (London, England)
Prevention and Control of Cardiovascular Disease in the Rapidly Changing Economy of China
Wu Y. et al, (2016), Circulation, 133, 2545 - 2560
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Wong MG. et al, (2016), Diabetes Care, 39, 694 - 700